ResearcherComprehensive Cancer Center ViennaNo recent work listed
Daniela Bianconi
Matched on ORCID iD 0000-0002-8102-4199; OpenAlex author ID A5043085369. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 8
- Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. Co-author DOI 10.7150/jca.70500↗
- Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Co-author DOI 10.2147/cmar.s308029↗
- Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm9030648↗
- SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. Co-author DOI 10.1016/j.tranon.2018.08.019↗
- A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Co-author DOI 10.1177/1758835919853196↗
- Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chem… Co-author DOI 10.1007/s12032-018-1223-3↗
- Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Co-author DOI 10.1007/s12254-017-0352-2↗
- Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Co-author DOI 10.1038/s41598-017-04743-0↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Matthias Unseld · 8 shared papers, 2017–2022 · strength 0.91
- Paper Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. DOI 10.7150/jca.70500↗
- Paper Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Seq… DOI 10.2147/cmar.s308029↗
- Paper Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreat… DOI 10.3390/jcm9030648↗
- Markus Kieler · 8 shared papers, 2017–2022 · strength 0.91
- Paper Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. DOI 10.7150/jca.70500↗
- Paper Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Seq… DOI 10.2147/cmar.s308029↗
- Paper Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreat… DOI 10.3390/jcm9030648↗
- Gerald W. Prager · 8 shared papers, 2017–2022 · strength 0.91
- Paper Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. DOI 10.7150/jca.70500↗
- Paper Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Seq… DOI 10.2147/cmar.s308029↗
- Paper Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreat… DOI 10.3390/jcm9030648↗
- Werner Scheithauer · 3 shared papers, 2017–2020 · strength 0.31
- Paper Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreat… DOI 10.3390/jcm9030648↗
- Paper A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil a… DOI 10.1177/1758835919853196↗
- Paper Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capec… DOI 10.1038/s41598-017-04743-0↗
- Berthold Streubel · 2 shared papers, 2017–2021 · strength 0.21
- Paper Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Seq… DOI 10.2147/cmar.s308029↗
- Paper Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capec… DOI 10.1038/s41598-017-04743-0↗
- J. Thaler · 1 shared paper, 2022 · strength 0.17
- Sukirthini Balendran · 1 shared paper, 2021 · strength 0.15
- Christoph Carl Zielinski · 2 shared papers, 2017–2019 · strength 0.15
- Martin Schindl · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.